Nan Hua Biology: Revenue of 385-425 million yuan in 2025, achieving a turnaround from loss to profit.

Nanhua Biotech announced that the company is expected to turn losses into profits by 2025, with revenue reaching 3.85-4.25 billion yuan, compared to 1.34 billion yuan in the same period last year. Net profit is projected to be 28.5-32.5 million yuan, a significant improvement from the 19.846 million yuan loss in the same period last year. The performance growth is attributed to the acquisition of a controlling stake in Loudi Jinhong New Materials, expansion of derivative product sales, implementation of cost reduction and efficiency enhancement measures, and an increase in government subsidies. However, this performance forecast is unaudited and subject to uncertainty. Following the implementation of the "delisting risk warning" on April 30, 2025, if certain conditions occur in the 2025 fiscal year, the company's stock may be delisted.